HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
|Articles|January 22, 2007
- Psychiatric Times Vol 24 No 1
- Volume 24
- Issue 1
Psychiatric Times Archives 2002
Psychiatric Times Archives 2002
Advertisement
December 2002
November 2002
October 2002
September 2002
August 2002
July 2002
June 2002
May 2002
April 2002
March 2002
February 2002
January 2002
Articles in this issue
almost 20 years ago
Antidepressants' Effects on Driving Abilityalmost 20 years ago
Green and Dyingalmost 20 years ago
Drugs for Kids: It's Time to Stop Medicating and Start Practicingalmost 20 years ago
Self-medication Prevalent in Patients With Anxiety Disordersalmost 20 years ago
Poetry of the Timesalmost 20 years ago
Congress Reduces Medicare Payment Cutalmost 20 years ago
Humorous Movies' Effects in Schizophreniaalmost 20 years ago
The Link Between Psychotic Disorders and Substance Usealmost 20 years ago
Intermittent Explosive Disorder: Common but Underappreciatedalmost 20 years ago
Accepting AcceptanceAdvertisement
Related to this article
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Neflamapimod for Dementia With Lewy Bodies Misses End Point, Subgroup Signal Emerges
5